Products - Pancreatic cancer | Topic | NICE

Showing 4 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer TSID 12040
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cabozantinib for treating advanced pancreatic or extra-pancreatic neuroendocrine tumours that have progressed after systemic treatment TSID 12078
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC